Valuation: StemRIM

Market Cap 18.68B 117M 100M 94.16M 86.01M 162M 11.18B 164M 1.11B 432M 5.64B 440M 431M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 73.36M 62.86M 58.9M 53.8M 102M 6.99B 103M 695M 270M 3.53B 275M 269M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
49.63%
Yield 2024 *
-
Yield 2025 -
1 day-0.28%
1 week+1.44%
Current month+18.46%
1 month+18.06%
3 months+20.48%
6 months+21.31%
Current year+34.22%
1 week 337
Extreme 337
368
1 month 280
Extreme 280
368
Current year 260
Extreme 260
368
1 year 246
Extreme 246
368
3 years 246
Extreme 246
881
5 years 246
Extreme 246
1,518
10 years 246
Extreme 246
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 30/09/2022
Chief Executive Officer 58 24/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 31/01/2007
Director/Board Member 58 28/02/2019
Director/Board Member 54 30/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%+1.44%+12.06%-59.28% 139M
+1.04%+3.09%+45.93%+0.60% 82.73B
+2.68%+29.00%-19.83%-34.19% 57.94B
+13.33%+149.08%+518.62%+40.11% 55.45B
+0.76%+2.39%+0.08%+35.11% 52.57B
+1.86%+3.13%+11.49%+174.36% 48.94B
+1.74%+4.16%+62.36%-16.27% 32.23B
+1.84%+5.49%+53.67%+103.96% 25.94B
+0.60%+4.98%+0.65%+188.89% 22.1B
+3.89%+1.08%+61.82%+112.10% 16.55B
Average +2.72%+16.14%+74.69%+54.54% 39.46B
Weighted average by Cap. +3.23%+21.98%+92.29%+47.81%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.69M -10.88M -10.19M -9.31M -17.57M -1.21B -17.74M -120M -46.8M -611M -47.66M -46.63M -1.93B -12.11M -10.38M -9.72M -8.88M -16.76M -1.15B -16.93M -115M -44.65M -582M -45.47M -44.48M
Net Debt -8.41B -52.8M -45.24M -42.39M -38.72M -73.08M -5.03B -73.8M -500M -195M -2.54B -198M -194M -6.99B -43.91M -37.63M -35.26M -32.2M -60.78M -4.19B -61.38M -416M -162M -2.11B -165M -161M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
25/08/26 JP¥353.00 -0.28% 327,900
24/08/26 JP¥354.00 -0.84% 306,700
21/08/26 JP¥357.00 +0.56% 495,100
20/08/26 JP¥355.00 +3.50% 383,200
19/08/26 JP¥343.00 -1.44% 492,700
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock